Kronos Bio has halted the development of istisociclib due to safety concerns from a clinical trial. Facing financial challenges, the company plans to explore strategic options and partnerships for its remaining assets, including KAT inhibitors for cancer and autoimmune disorders.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing